| Dr Terata Ann Kanu, MD | |
|
18th Medical Group, Unit 5142, Apo, AE 96368-5142 | |
| (315) 630-4315 | |
| Not Available |
| Full Name | Dr Terata Ann Kanu |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 13 Years |
| Location | 18th Medical Group, Apo, Armed Forces Europe |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376842591 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207PE0004X | Emergency Medicine - Emergency Medical Services | 29458 (Oklahoma) | Secondary |
| 208D00000X | General Practice | 29458 (Oklahoma) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Doctors For A Better Tomorrow Pllc | 6608157763 | 3 |
News Archive
In the race to protect society from infectious microbes, the bugs are outrunning us. The need for new therapeutic agents is acute, given the emergence of novel pathogens as well as old foes bearing heightened antibiotic resistance.
People rely on a highly tuned sense of touch to manipulate objects, but injuries to the skin and the simple act of wearing gloves can impair this ability.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine (Xeloda) as a treatment for advanced, metastatic colorectal cancer.
AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.
› Verified 4 days ago
| Entity Name | Doctors For A Better Tomorrow Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306390596 PECOS PAC ID: 6608157763 Enrollment ID: O20170103001398 |
News Archive
In the race to protect society from infectious microbes, the bugs are outrunning us. The need for new therapeutic agents is acute, given the emergence of novel pathogens as well as old foes bearing heightened antibiotic resistance.
People rely on a highly tuned sense of touch to manipulate objects, but injuries to the skin and the simple act of wearing gloves can impair this ability.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine (Xeloda) as a treatment for advanced, metastatic colorectal cancer.
AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.
› Verified 4 days ago
| Entity Name | Open Arms Healthcare Of Texas Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639656325 PECOS PAC ID: 9436400579 Enrollment ID: O20180928000718 |
News Archive
In the race to protect society from infectious microbes, the bugs are outrunning us. The need for new therapeutic agents is acute, given the emergence of novel pathogens as well as old foes bearing heightened antibiotic resistance.
People rely on a highly tuned sense of touch to manipulate objects, but injuries to the skin and the simple act of wearing gloves can impair this ability.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine (Xeloda) as a treatment for advanced, metastatic colorectal cancer.
AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Terata Ann Kanu, MD Psc 80, Box 13314, Apo, AP 96367-9998 Ph: (315) 630-4780 | Dr Terata Ann Kanu, MD 18th Medical Group, Unit 5142, Apo, AE 96368-5142 Ph: (315) 630-4315 |
News Archive
In the race to protect society from infectious microbes, the bugs are outrunning us. The need for new therapeutic agents is acute, given the emergence of novel pathogens as well as old foes bearing heightened antibiotic resistance.
People rely on a highly tuned sense of touch to manipulate objects, but injuries to the skin and the simple act of wearing gloves can impair this ability.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine (Xeloda) as a treatment for advanced, metastatic colorectal cancer.
AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.
› Verified 4 days ago
Virginia Ann Phillips, General Practice Medicare: Medicare Enrolled Practice Location: Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 Phone: 314-590-4221 | |
Sean Brugman, M.D. General Practice Medicare: Medicare Enrolled Practice Location: Bdaach, Camp Humphreys - Bld 3130, Pyeongtaek, S. Korea, Apo, AE 96205 Phone: 031-690-7911 | |
James Austin Stewart, D.O. General Practice Medicare: Medicare Enrolled Practice Location: Usa Meddac Bavaria, Cmr 411 Bldg 700, Apo, AE 09112 Phone: 314-590-3760 | |
Dr. Scott Jacob Andrews, D.O. General Practice Medicare: Medicare Enrolled Practice Location: 52 Mdg, Unit 3690, Apo, AE 09126 Phone: 314-452-8285 | |
Nyomi Washington, MD General Practice Medicare: Medicare Enrolled Practice Location: Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 Phone: 314-590-8298 | |
Dr. Jessica Kathleen Rouse, MD General Practice Medicare: Medicare Enrolled Practice Location: Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 Phone: 314-590-5762 | |
Dr. Tiffany Celeste Winston, M.D. General Practice Medicare: Medicare Enrolled Practice Location: Landstuhl Regional Medical Center Unit 33100, Apo, AE 09180 Phone: 314-590-6322 |